Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised …

…, JP Mira, JM Molina, X Monnet, J Mootien… - The Lancet infectious …, 2022 - thelancet.com
Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversial.
We aimed to evaluate the clinical efficacy of remdesivir plus standard of care compared with …

[HTML][HTML] Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March …

…, C Le Hyaric, T Fabacher, J Mootien… - …, 2020 - eurosurveillance.org
Background In March 2020, the COVID-19 outbreak was declared a pandemic by the World
Health Organization. Aim Our objective was to identify risk factors predictive of severe …

[HTML][HTML] An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients …

…, C Dubost, J Courjon, S Leroy, J Mootien… - Clinical Microbiology …, 2021 - Elsevier
Objectives We evaluated the clinical, virological and safety outcomes of lopinavir/ritonavir,
lopinavir/ritonavir–interferon (IFN)-β-1a, hydroxychloroquine or remdesivir in comparison to …

[HTML][HTML] Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase …

…, K Tonby, A Gaudet, L Heggelund, J Mootien… - Critical care, 2023 - Springer
Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no
placebo-controlled trials have focused specifically on severe/critical COVID, including …

Haemophagocytosis in bone marrow aspirates in patients with COVID‐19

A Debliquis, I Harzallah, JY Mootien… - British Journal of …, 2020 - ncbi.nlm.nih.gov
Discussion COVID‐19 may show varying presentation. 6 Our report highlights the presence
of haemophagocytosis in these three cases of COVID‐19 presenting with different clinical …

[HTML][HTML] Epidemiology and prognosis of intensive care unit–acquired bloodstream infection

…, M Roy, C Mayence, C Mathien, J Mootien… - The American journal …, 2020 - ncbi.nlm.nih.gov
Intensive care unit–acquired bloodstream infections (ICU-BSI) are frequent and are
associated with high morbidity and mortality rates. We conducted this study to describe the …

[HTML][HTML] The place of new antibiotics for Gram-negative bacterial infections in intensive care: Report of a consensus conference

…, O Hamzaoui, V Lemiale, J Maizel, JY Mootien… - Annals of Intensive …, 2023 - Springer
Introduction New beta-lactams, associated or not with beta-lactamase inhibitors (NBs/BIs),
can respond to the spread of carbapenemase-producing enterobacteriales and …

Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19

…, JP Mira, JM Molina, X Monnet, J Mootien… - The Lancet Infectious …, 2022 - thelancet.com
We reported the preliminary results of the DisCoVeRy trial regarding the efficacy and safety
of remdesivir in hospitalised patients with COVID-19 in February, 2022. 1 Remdesivir did not …

Clinical usefulness of 18F–FDG PET/CT for initial staging and assessment of treatment efficacy in patients with lymph node tuberculosis

N Lefebvre, X Argemi, N Meyer, J Mootien… - Nuclear medicine and …, 2017 - Elsevier
Introduction Few studies have evaluated the promising role of 18 F–fluoro-2-deoxy-D-glucose
positron emission tomography (PET) and PET/computed tomography FDG PET/CT in …

The BAS2IC Score: A Useful Tool to Identify Patients at High Risk of Early Progression to Severe Coronavirus Disease 2019

…, T Fabacher, O Hinschberger, J Mootien… - Open Forum …, 2020 - academic.oup.com
Joy Mootien , Joy Mootien … Charlotte Kaeuffer, Yvon Ruch, Thibaut Fabacher, Olivier
Hinschberger, Joy Mootien, Magali Eyriey, Valentin Greigert, COVID-19 Alsace Study Group …